AcouSort AB (publ)

AcouSort AB (publ) is a technology firm that innovates and provides automated systems for preparing biological samples. Their core methodology relies on acoustofluidics technology, catering to the needs of the research community and various life science organizations. The company's product portfolio includes several key offerings: AcouTrap: A compact laboratory instrument engineered for preparing samples containing cells, extracellular vesicles, bacteria, and viruses from diverse biological media. AcouPlasma: An integrated module capable of separating blood plasma directly from whole blood, enabling seamless in-line analytical processes. AcouWash: Another benchtop device designed for the label-free isolation of specific target cells from a wide array of samples. Established in 2010, AcouSort is headquartered in Lund, Sweden.

AcouSort AB (publ) trades as ACOU.ST on STO. The company is classified in Healthcare / Biotechnology and reports in SEK.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

AcouSort AB (publ) can be compared against peers such as Alligator Bioscience AB (publ), ExpreS2ion Biotech Holding AB (publ), Lipigon Pharmaceuticals AB (publ), Modus Therapeutics Holding AB (publ), Newbury Pharmaceuticals AB (publ), OncoZenge AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $90.79M, beta of 0.10, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ACOU.ST currently shows total debt of N/A and beta of 0.10. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.acousort.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.